



Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea

Claudia Baratto¹, Andrea Faini ^{1,2}, Gianluca P. Gallone¹, Céline Dewachter³, Giovanni B. Perego ¹, Antoine Bondue³, Denisa Muraru^{1,4}, Michele Senni^{4,5}, Luigi P. Badano^{1,4}, Gianfranco Parati ^{1,4}, Jean-Luc Vachiéry³ and Sergio Caravita ^{1,6}

¹Department of Cardiology, Istituto Auxologico Italiano IRCCS, Ospedale San Luca, Milan, Italy. ²Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy. ³Department of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Brussels, Belgium. ⁴Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. ⁵Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy. ⁶Department of Management, Information and Production Engineering, University of Bergamo, Dalmine, Italy.

Corresponding author: Sergio Caravita (s.caravita@auxologico.it and sergio.caravita@unibg.it)



Shareable abstract (@ERSpublications)

PAWP provides accurate but imprecise estimates for LVEDP during exercise. A combination of PAWP ≥ 25 mmHg at peak and/or PAWP/CO slope > 2 mmHg·L⁻¹·min⁻¹ correctly identify HFpEF patients among those individuals with either PAWP or LVEDP ≥ 25 mmHg at peak. <https://bit.ly/3wTCSsX>

Cite this article as: Baratto C, Faini A, Gallone GP, et al. Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea. *ERJ Open Res* 2023; 9: 00750-2022 [DOI: 10.1183/23120541.00750-2022].

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 27 Dec 2022
Accepted: 29 Jan 2023

Abstract

Background Pulmonary artery wedge pressure (PAWP) during exercise, as a surrogate for left ventricular (LV) end-diastolic pressure (EDP), is used to diagnose heart failure with preserved ejection fraction (HFpEF). However, LVEDP is the gold standard to assess LV filling, end-diastolic PAWP (PAWP_{ED}) is supposed to coincide with LVEDP and mean PAWP throughout the cardiac cycle (PAWP_M) better reflects the haemodynamic load imposed on the pulmonary circulation. The objective of the present study was to determine precision and accuracy of PAWP estimates for LVEDP during exercise, as well as the rate of agreement between these measures.

Methods 46 individuals underwent simultaneous right and left heart catheterisation, at rest and during exercise, to confirm/exclude HFpEF. We evaluated: linear regression between LVEDP and PAWP, Bland–Altman graphs, and the rate of concordance of dichotomised LVEDP and PAWP \geq or $<$ diagnostic thresholds for HFpEF.

Results At peak exercise, PAWP_M and LVEDP, as well as PAWP_{ED} and LVEDP, were fairly correlated ($R^2 > 0.69$, $p < 0.01$), with minimal bias (+2 and 0 mmHg respectively) but large limits of agreement (± 11 mmHg). 89% of individuals had concordant PAWP and LVEDP \geq or < 25 mmHg (Cohen's $\kappa = 0.64$). Individuals with either LVEDP or PAWP_M ≥ 25 mmHg showed a PAWP_M increase relative to cardiac output (CO) changes (PAWP_M/CO slope) > 2 mmHg·L⁻¹·min⁻¹.

Conclusions During exercise, PAWP is accurate but not precise for the estimation of LVEDP. Despite a good rate of concordance, these two measures might occasionally disagree.

Introduction

Heart failure with preserved ejection fraction (HFpEF) can be considered a clinical syndrome of cardiovascular ageing, ensuing from a combination of increased left ventricular diastolic stiffness and increased stressed blood volume (or dysfunctional preload) [1–3]. Symptoms may occur despite euvolaemia at physical examination and normal natriuretic peptides, as well as with normal filling pressures at rest, either estimated through echocardiography or directly measured by cardiac catheterisation [4–6]. To overcome this diagnostic challenge, invasive exercise haemodynamic testing has been suggested to unmask HFpEF, allowing to detect a steep increase in pulmonary artery wedge pressure (PAWP), with peak PAWP values ≥ 25 mmHg as the hallmark of the disease [5–7]. All this reasoning is based upon the assumption that PAWP approximates left ventricular (LV) end-diastolic pressure (EDP). However, LVEDP reflects LV diastolic stiffness more directly than PAWP, without the interposition of the left atrium (LA) and of the



pulmonary circulation, while PAWP reflects the haemodynamic load imposed by the left heart on the pulmonary vascular bed and on the right heart [8]. Thus, it might be supposed that, during exercise, PAWP and LVEDP may disagree, potentially questioning the diagnosis of HFpEF in a number of individuals, especially when absolute cut-off values are employed, taking into account the methodological heterogeneity in PAWP measurement during exercise haemodynamics across centres, as well as the absence of an undisputed gold-standard reference [9]. Additionally, the accuracy and precision of PAWP as a surrogate of LVEDP has been reported in resting condition only, both for end-diastolic PAWP (PAWP_{ED}) and for PAWP averaged over the cardiac cycle, *i.e.* mean PAWP (PAWP_M) [10–14]. Thus, the primary aim of our study was to compare LVEDP and PAWP during exercise in a cohort of consecutive patients referred for exercise cardiac catheterisation, in order to assess the validity of the latter as an estimate of the former. Anticipating that PAWP and LVEDP may occasionally disagree, we also exploratively aimed to verify whether additional haemodynamic parameters (*i.e.* flow-normalised PAWP trajectories) may reinforce the diagnosis of HFpEF in patients with either PAWP or LVEDP equal or above the arbitrary pathological threshold of 25 mmHg.

Methods

This study was approved by the Ethics Committee of the Istituto Auxologico Italiano (protocol n 2020_04_21_03). We included consecutive patients with exertional breathlessness referred for elective cardiac catheterisation in stable clinical conditions to confirm or exclude the diagnosis of HFpEF, who signed an informed consent for the use of their data for research purposes. Additionally, they needed to have been instrumented with both a Swan–Ganz catheter in the pulmonary artery and a pig-tail catheter in the left ventricle, and to have completed a symptom-limited step-incremental exercise test in the supine position. Finally, they needed to have readable LVEDP at peak exercise. We excluded patients who had not performed a left heart catheterisation, those with reduced LV ejection fraction (<50%), restrictive or hypertrophic or infiltrative cardiomyopathy, congenital heart disease, constrictive pericarditis and myocardial ischaemia, as well as those with a clinical and haemodynamic diagnosis of pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) [15], more than moderate respiratory disorders, more than mild primary valvular regurgitation and any valvular stenosis. We also excluded unstable patients (non-elective hospitalisation, rapid worsening of symptoms, haemodynamic compromise) and individuals not able to perform a physical exercise on a supine cycle ergometer.

Clinical and echocardiographic data, obtained at the time of a structured assessment preceding the indication to cardiac catheterisation, were abstracted from clinical charts. Echocardiography was performed by experienced cardiologists following current recommendations [16]. Images were stored in digital format for quantitative analysis, which was performed by trained personnel, blinded to clinical and haemodynamic data. The pre-test probability of HFpEF was assessed through the H₂FPEF score [17]. The H₂FPEF score is a continuous score with higher values associated with higher probability of HFpEF. For practical reasons, we considered HFpEF “likely” in those patients with an H₂FPEF score >4 (probability >70%), HFpEF “possible” in those with a H₂FPEF score 2–4 (probability 40–70%) and HFpEF “unlikely” in those with a H₂FPEF score <2 (probability <40%) [4].

Right heart catheterisation

Patients were studied on chronic medications, in the fasting state, without sedation, in supine position. They wore a non-rebreathing Hans-Rudolph mask connected to the V-MAX metabolic cart (Vmax SensorMedics 2200, Yorba Linda, CA, USA) to measure oxygen consumption directly. A 7-F fluid-filled Swan–Ganz catheter was placed in the pulmonary artery through the right internal jugular vein under fluoroscopic guidance. Proper pulmonary artery wedge positioning was confirmed by the appearance of a typical PAWP trace as well as by an oxygen saturation >94% sampled at the tip of the catheter. A 5-F pig-tail catheter was placed in the LV through a 6-F right radial artery sheath. The transducers were zeroed at the midthoracic line, halfway between the anterior sternum and the bed surface using a laser caliper. Haemodynamic measurements were performed at rest, after 1 min of passive leg raise (feet on the pedals), and during the last minute of each step of a symptom-limited exercise test. The increment in workload was personalised in order to obtain at least three steps of exercise before exhaustion [4]. 2 mL of blood was sampled at the same time from the tip of the Swan–Ganz catheter and from the radial artery, in order to calculate cardiac output (CO) by the direct Fick method.

Pressures were measured at end-expiration and averaged over several (at least five) respiratory cycles. Additionally, PAWP was measured:

- at end-diastole (PAWP_{ED}): at mid-A for patients in sinus rhythm, at mid-C – when visible – or at pre-V for patients in atrial fibrillation;
- averaging PAWP throughout the cardiac cycle (mean PAWP or PAWP_M).

V waves were measured on the PAWP waveform, and their amplitude was calculated as the difference between the zenith of the V wave and the mean PAWP value. A linear regression was applied to multiple pairs of PAWP and CO points, in order to calculate the PAWP/CO slope [4, 6]. The speed sweep was adapted to visualise LVEDP better despite increasing heart rate during exercise.

Haemodynamic data reflect the agreement of two expert independent readers blinded to patients' data, who visually reviewed all pressure traces offline.

HFpEF was defined by either an end-expiratory PAWP_M or LVEDP >15 mmHg at rest and/or ≥25 mmHg at peak exercise. In case of disagreement between these two variables at peak exercise, an end-expiratory PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹ was considered as an additional haemodynamic parameter indicative of HFpEF [4, 9, 14].

Statistical analysis

Continuous variables are reported as mean±SD when normally distributed and as median (IQR) otherwise. Categorical data are showed as absolute number (%). The agreement and the relationship between LVEDP and PAWP at different conditions was tested by Bland–Altman analysis and linear regression analysis, respectively, while the reliability of agreement was assessed using Cohen's κ.

Results

General characteristics

Out of 96 exercise cardiac catheterisations performed between June 2019 and March 2021, 50 patients presented with exclusion criteria (secondary forms of HFpEF, pulmonary vascular diseases, more than mild primary valvular regurgitation, congenital heart disease). 46 patients fulfilled the inclusion criteria and were analysed.

General clinical characteristics of the study cohort are reported in table 1. Mean age was 71 years, 67% of individuals were females and mean body mass index was 27 kg·m⁻². Cardiovascular risk factors were well represented (79% with arterial hypertension, 22% obese, 15% with diabetes mellitus or impaired glucose tolerance, 15% with stable coronary artery disease). The majority of patients were in sinus rhythm at the time of cardiac catheterisation. Median brain natriuretic peptide was 106 ng·L⁻¹, median LA volume index was 34 mL·m⁻², mean E/E' was 10 and systolic pulmonary arterial pressure was estimated at 36 mmHg. The pre-test probability of HFpEF, calculated based on the H₂FPEF score, was low in 13%, intermediate in 48% and high in 39% of individuals (figure 1).

Rest and exercise haemodynamics

Rest and exercise end-expiratory haemodynamic data for the whole cohort are reported in table 2.

From rest to peak exercise, end-expiratory PAWP_M increased in median from 14 (9–18) to 33 (26–41) mmHg, PAWP_{ED} from 14 (9–17) to 31 (25–38) mmHg, LVEDP from 15 (10–20) to 30 (25–36) mmHg. Respiratory-averaged PAWP_M increased in median from 10 (6–15) to 26 (22–34) mmHg, PAWP_{ED} from 10 (7–14) to 25 (20–30) mmHg, LVEDP from 13 (8–17) to 26 (21–30) mmHg. CO increased from 4.6 (3.6–5.9) L·min⁻¹ at rest to 8.8 (7.1–11.2) L·min⁻¹ at peak. 26% of patients had a PAWP V wave amplitude at peak exercise >5 mmHg.

Linear regression analysis and Bland–Altman plot of end-expiratory rest and peak exercise LVEDP versus PAWP (both PAWP_{ED} and PAWP_M) are reported in the figure 1. Mean bias for end-expiratory PAWP_{ED} versus LVEDP at peak exercise was minimal (+0.11 mmHg) but with large confidence intervals (±10.76 mmHg). At peak exercise, end-expiratory PAWP_M overestimated LVEDP by 2 mmHg, again with large confidence intervals (±11.35 mmHg). Linear regression analysis and Bland–Altman plot of respiratory-averaged LVEDP versus PAWP are reported in figure 2 (at rest) and figure 3 (peak exercise).

Concordance between LVEDP and PAWP

At rest, 46% of individuals had either an end-expiratory PAWP_M or a LVEDP >15 mmHg, and 57% had a respiratory-averaged PAWP_M and/or a LVEDP >15 mmHg (figure 1). The rate of concordance of these two so-dichotomised measures at rest was 78%, with moderate agreement (Cohen's κ=0.56).

During exercise, 80% and 83% of individuals had either an end-expiratory PAWP_M or LVEDP ≥25 mmHg. 87% of cases had an end-expiratory PAWP_M and/or LVEDP ≥25 mmHg (figure 1). The two so-dichotomised measures were concordant in 89% of cases with substantial agreement (Cohen's κ=0.64). In particular, three patients had an end-expiratory PAWP_M ≥25 mmHg but a LVEDP <25 mmHg, and two

TABLE 1 General characteristics of the study population

Demographics and anthropometrics	
Age years	71±9
Female sex	31 (67)
BMI kg·m ⁻²	27±6
Comorbidities and cardiovascular risk factors	
Obesity	10 (22)
Arterial hypertension	36 (79)
Diabetes mellitus or impaired glucose tolerance	7 (15)
Coronary artery disease	7 (15)
Sinus rhythm	42 (91)
Paroxysmal or persistent atrial fibrillation	9 (20)
Permanent atrial fibrillation	4 (9)
COPD	10 (22)
Blood tests	
Creatinine mg·dL ⁻¹	0.9±0.2
Haemoglobin g·dL ⁻¹	13.1±1.6
BNP ng·L ⁻¹	106 (51–240)
Echocardiography	
Interventricular septum thickness mm	10.4±1.3
Posterior wall thickness mm	9.4±1.3
LV mass index g·m ⁻²	85 (73–103)
LV EDV mL	85 (77–103)
LV ejection fraction %	64±6
LA volume index mL·m ⁻²	34 (26–49)
E/E' avg	10±4
Estimated sPAP mmHg	36±8
HFpEF probability	
H ₂ FPEF score	4±2
Low	6 (13)
Intermediate	22 (48)
High	18 (39)

Data are expressed as mean±sd, median (Q₁–Q₃) or n (%). BMI: body mass index; BNP: brain natriuretic peptide; COPD: chronic obstructive pulmonary disease; EDV: end-diastolic volume; HFpEF: heart failure with preserved ejection fraction; LA: left atrium; LV: left ventricle; sPAP: systolic pulmonary arterial pressure.

patients had a LVEDP ≥25 mmHg but a PAWP_M <25 mmHg. All of these five patients, with discordant PAWP_M and LVEDP, had a PAWP_M/CO slope >2 mmHg·L⁻¹·min⁻¹.

Discussion

To the best of our knowledge, this is the first study comparing PAWP and LVEDP measurements obtained during exercise. Thus, obtaining LVEDP during supine exercise is feasible in patients with exertional breathlessness and/or suspicion of HFpEF. We could show a good accuracy (minimal mean bias) but a relevant imprecision (large confidence intervals) of PAWP estimates for LVEDP. This result was consistent in several scenarios: 1) both at rest and at peak exercise; and 2) both when these variables were measured at end-expiration (as is commonly done in many US centres [5, 6]) and when they were averaged over the respiratory cycle (as recommended by the European Respiratory Society when large respiratory swings are present, including during physical exercise [18]). The imprecision of PAWP estimates for LVEDP could have contributed to a small but not negligible discordance of these two variables (in 11% of patients) when both were arbitrarily dichotomised at ≥25 mmHg at end-expiration at peak exercise to diagnose HFpEF. However, our preliminary results suggest that the incorporation of additional measures (*i.e.*, PAWP/CO slope) could overcome such modest discordance: all patients with either PAWP or LVEDP above diagnostic cut-off for LVEDP also had a PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹.

LVEDP represents the operational pressure of the LV at end-diastole. Accordingly, it is generally viewed as a suitable marker of diastolic stiffness, albeit simplifying the gold-standard pressure–volume LV curve to one pressure point [19]. However, this measure is generally felt to be more “invasive” and riskier than PAWP. LVEDP has been rarely employed during exercise for the diagnosis of HFpEF, with lower evidence on pathological LVEDP thresholds to diagnose this disease [5]. Nonetheless, LVEDP measurement might be attractive, since obtaining a reliable PAWP tracing might not always be possible in all patients [14].






FIGURE 1 Accuracy and precision of end-expiratory PAWP_{ED} and PAWP_M estimates for LVEDP, as well as the rate of agreement of PAWP and LVEDP for the diagnosis of HFpEF at rest and during exercise in our population. The pre-test probability of HFpEF in our cohort was intermediate-high based on the H₂FPEF score. Exemplificative pressure trace recordings (LV pressure, red; PAWP, blue) are shown both at rest and during exercise. Linear regression analysis and Bland-Altman plot of end-expiratory LVEDP *versus* PAWP values are shown both at rest and at peak exercise. Both for rest and peak exercise, **a and b**) PAWP values are reported both at end-diastole (*i.e.* mid-A wave for patients in sinus rhythm; mid-C or pre-V wave for patients in atrial fibrillation) and **c and d**) averaged over the cardiac cycle (mean PAWP). Venn diagrams show the agreement of dichotomised PAWP and LVEDP values above the diagnostic threshold to diagnose HFpEF, both at rest and at peak exercise. Agreement between PAWP and LVEDP was higher during exercise than at rest. Despite substantial agreement at peak exercise, five individuals had either PAWP or LVEDP above the diagnostic threshold for HFpEF. All of them presented with a PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹, suggesting that incorporation of flow-corrected PAWP in the definition of HFpEF (PAWP ≥25 mmHg and/or PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹) may maximise the diagnostic yield of exercise right heart catheterisation. CO: cardiac output; ED: end-diastolic; HFpEF: heart failure with preserved ejection fraction; LV: left ventricular; LVEDP: left ventricular end-diastolic pressure; M: mean; PAWP: pulmonary artery wedge pressure.

Despite this, a left heart catheterisation alone may carry less information than a right heart catheterisation: the latter incorporates pressures and flows of the pulmonary circulation; PAWP_{ED} (mid-A or mid-C) is believed to be a good surrogate of LVEDP; and PAWP_M provides additional information over LVEDP on left heart filling pressures [8]. Indeed, the LA may not be a passive bystander in HFpEF: LA “myopathy”, either due to intrinsically reduced LA compliance or to an upward shift of the LA compliance curve, might frequently manifest with tall (systolic) V waves in the PAWP position, increasing PAWP_M well beyond PAWP_{ED} and LVEDP [20, 21]. Accordingly, V wave amplitude >5 mmHg at peak exercise was present in one quarter of our patient population, likely contributing to elevate median PAWP_M slightly above PAWP_{ED} and LVEDP, irrespectively of the respiratory phase. To take into account the role of the LA in the clinical manifestations of HFpEF [20, 21], it seems thus reasonable to prefer end-expiratory PAWP_M over PAWP_{ED} (and LVEDP) for diagnostic purposes.

In analogy to our results obtained during supine exercise, clinical studies comparing PAWP and LVEDP in resting conditions have overall shown a moderate to good accuracy (minimal bias) but a large imprecision (wide limits of agreement) of PAWP estimates for LVEDP [10–14].

HALPERN *et al.* [10] reported data from 3926 patients (85% with a PAWP >15 mmHg) with an indication to LV ventriculography or coronary angiography, who were studied over 10 years by 10 physicians, without pressure trace re-reading. PAWP was recorded at rest as a mean pressure (PAWP_M), while LVEDP was taken following the A wave “in some patients”. They found that, at end-expiration, PAWP_M slightly underestimated LVEDP by 2.9 mmHg.

TABLE 2 Rest and exercise haemodynamics of the study population; end-expiratory pressure measurements are reported

	Rest	Peak exercise
Workload W		50 (40–75)
HR bpm	69 (60–76)	110 (97–122)
HR % of predicted		74 (66–82)
Systolic BP mmHg	144 (136–155)	180 (160–195)
Diastolic BP mmHg	73 (64–80)	87 (75–100)
Mean PAP mmHg	20 (16–25)	40 (37–49)
LVEDP mmHg	15 (10–20)	30 (25–36)
PAWP _M mmHg	14 (9–18)	33 (26–41)
PAWP _{ED} mmHg	14 (9–17)	31 (25–38)
PAWP _M /CO slope mmHg·L ⁻¹ ·min ⁻¹		2.4 (1.8–4.3)
PAWP, V wave mmHg	15 (10–24)	38 (32–48)
Mean RAP mmHg	6 (4–8)	16 (12–22)
CO L ⁻¹ ·min ⁻¹	4.6±1.5	8.8 (7.1–11.2)
CI L ⁻¹ ·min ⁻¹ ·m ⁻²	2.6±0.7	5.1 (4.1–6.2)

Data are expressed as mean±SD or median (Q₁–Q₃). HR: heart rate; BP: blood pressure; PAP: pulmonary arterial pressure; LVEDP: left ventricular end-diastolic pressure; PAWP_{ED}: end-diastolic pulmonary artery wedge pressure; PAWP_M: mean pulmonary artery wedge pressure; CO: cardiac output; RAP: right atrial pressure; CI: cardiac index.




FIGURE 2 Linear regression analysis and Bland–Altman plot of respiratory-averaged LVEDP *versus* PAWP values at rest. Bland–Altman plot and linear regression analysis between end-diastolic PAWP (measured at mid-A in sinus rhythm, at mid-C or pre-V in atrial fibrillation) and LVEDP are shown in panels a) and b). Bland–Altman plot and linear regression analysis between mean PAWP (PAWP averaged over the cardiac cycle) and LVEDP are shown in panels c) and d). LVEDP: left ventricular end-diastolic pressure; PAWP_{ED}: end-diastolic pulmonary artery wedge pressure; PAWP_M: mean pulmonary artery wedge pressure.

RYAN *et al.* [11] studied 61 patients at rest (59% with PAH), and compared PAWP_M (both end-expiratory and respiratory-averaged) and LVEDP measured at the C-point or at the point of upslope of the R wave at ECG. They found a slight overestimation (by 0.9 mmHg) of PAWP_M *versus* LVEDP when these variables were both measured at end-expiration, and an underestimation (by 4.4 mmHg) when the variables were averaged over several respiratory cycles.

BITAR *et al.* [12] reported computer-generated values of haemodynamics measurements of 101 patients (58% with PH, three-quarters of whom were post-capillary). They found that digitalised, respiratory-averaged PAWP_M underestimated LVEDP by 2.9 mmHg.

OLIVEIRA *et al.* [13] studied 105 patients (79% with PAWP <15 mmHg) and found that, at end-expiration, PAWP_{ED} had a good accuracy (mean bias +0.3 mmHg) to estimate LVEDP, the latter measured at the C-point.

DICKINSON *et al.* [14] studied a quite heterogeneous cohort of patients, 57% of whom presented with post-capillary PH. Automated, respiratory-averaged PAWP_M slightly underestimated LVEDP measured at




FIGURE 3 Linear regression analysis and Bland–Altman plot of respiratory-averaged LVEDP versus PAWP values at peak exercise. Bland–Altman plot and linear regression analysis between end-diastolic PAWP (measured at mid-A in sinus rhythm, at mid-C or pre-V in atrial fibrillation) and LVEDP are shown in panels a) and b). Bland–Altman plot and linear regression analysis between mean PAWP (PAWP averaged over the cardiac cycle) and LVEDP are shown in panels c) and d). LVEDP: left ventricular end-diastolic pressure; PAWP_{ED}: end-diastolic pulmonary artery wedge pressure; PAWP_M: mean pulmonary artery wedge pressure.

the Z point by 0.8 mmHg. However, when separating the population based on the presence of sinus rhythm or of atrial fibrillation (the latter as a marker of left atrial dysfunction), they found that respiratory-averaged PAWP_M overestimated LVEDP in atrial fibrillation (by 5 mmHg) and underestimated LVEDP in sinus rhythm (by 3 mmHg).

Thus, results coming from the literature are quite heterogeneous, both in terms of sample size, patients' population being investigated, methodology and timing of pressure measurement over the respiratory and cardiac cycle, as well as results obtained. Indeed, some investigators found a small but potentially relevant underestimation (by 2–4 mmHg) either of respiratory-averaged PAWP_M or end-expiratory PAWP_M, one study highlighted an overestimation of LVEDP by PAWP in patients with atrial fibrillation (as a marker of left atrial dysfunction/myopathy), while others showed the absence of a relevant bias of PAWP (especially PAWP_{ED}) estimates for LVEDP. However, all the studies are homogeneous in pointing to a relevant imprecision (large confidence intervals) of PAWP estimates for LVEDP in resting condition, indicating that these two measures may not coincide in an individual patient [10–14]. Even though PAWP and LVEDP are supposed to have a similar meaning (and accordingly they are fairly correlated with minimal albeit

potentially relevant bias), intra-individual differences might be expected, either due to intrinsic limitation of pressure measurements with fluid-filled catheters, measurement errors (as for any physiological measurement), or to the fact that PAWP and LVEDP are measured in different sites of the cardiovascular system or in different time frames of the cardiac cycle. Our results, obtained during physical exercise in a quite homogeneous patients' cohort investigated with exertional dyspnoea and/or suspicion of HFpEF, are overall in agreement with these previous reports obtained in resting conditions, by showing large imprecision (wide limits of agreement) and a minimal bias of PAWP (especially of PAWP_M), anyhow measured, in comparison with LVEDP.

Notably, a minimal bias, together with the large limits of agreement, may be clinically relevant in those individuals with left heart filling pressure values close to the thresholds adopted to discriminate pre-capillary from post-capillary PH, as well as to diagnose or exclude HFpEF during exercise. This is why provocative testing in the catheterisation laboratory is increasingly integrated with a pre-test probability assessment of HFpEF, in order to obtain a consistent and definitive diagnosis when resting haemodynamics lay in a "grey zone" [22, 23]: the dynamic, multipoint evaluation during provocative manoeuvres may minimise and overcome the impact of aleatory fluctuations in haemodynamics at rest as well as error measurements. In line with this reasoning, the rate of concordance between end-expiratory PAWP_M and LVEDP was slightly higher during exercise than at rest, indirectly highlighting the importance of provocative manoeuvres to unmask HFpEF. Despite this, five individuals (11%) reached either the end-expiratory LVEDP or the PAWP_M threshold ≥ 25 mmHg at peak exercise. Interestingly, all of them presented also with a PAWP_M/CO slope > 2 mmHg as an additional criterion supporting the diagnosis of HFpEF. Even though this is a marginal and exploratory result on a limited sample size, we suggest that incorporation of the PAWP/CO slope in the definition of HFpEF (*e.g.* end-expiratory PAWP ≥ 25 mmHg and/or PAWP/CO slope > 2 mmHg·L⁻¹·min⁻¹) might help support the haemodynamic diagnosis of this condition, possibly overcoming the limitations of a solitary PAWP measurement at peak exercise [4, 16, 24].

Limitations

This study was conducted on a relatively small number of highly selected patients, mainly at intermediate or high pre-test probability of HFpEF based on the H₂FPEF score (48% and 39% of our cohort, respectively), and the majority of them were eventually found to have HFpEF based on exercise haemodynamic results. From a clinical perspective, it represents the cohort of patients in whom LVEDP measurement might be expected to be most informative for diagnostic purposes. However, these results may deserve validation in cohorts of patients without HFpEF, or with additional confounding factors (pre-capillary PH, severe respiratory disorders or severe obesity). Nonetheless, we expect that obtaining LVEDP measures during exercise in patients with a small LV (such as patients with pulmonary vascular diseases) could be more challenging because of a higher likelihood of the pig-tail catheter to mechanically trigger ventricular ectopic beats.

Additionally, we arbitrarily defined as "pathological" an end-expiratory LVEDP at peak ≥ 25 mmHg, in the absence of validated reference values for this variable. However, PAWP, whose diagnostic and prognostic role in HFpEF is nowadays undisputed [25], was found to be fairly correlated with LVEDP. Thus, the adoption of an end-expiratory cut-off value at peak ≥ 25 mmHg might be reasonable for both variables.

Conclusions

PAWP and LVEDP are fairly correlated both at rest and during exercise in a population with exertional breathlessness and suspicion of HFpEF. While PAWP_{ED} had no relevant bias as compared with LVEDP, PAWP_M slightly overestimated LVEDP, likely due to concomitant left atrial dysfunction, increasing PAWP_M values over end-diastolic values. This adequate accuracy of exercise PAWP *versus* LVEDP (minimal or no bias) is counterbalanced by relevant imprecision. However, the rate of agreement of these variables, dichotomised based on currently adopted PAWP cut-offs to diagnose HFpEF, increases from rest to exercise. In particular, when arbitrarily assuming an end-expiratory cut-off value to diagnose HFpEF of ≥ 25 mmHg for both end-expiratory PAWP_M and end-expiratory LVEDP, these two measures might only occasionally disagree, questioning or preventing the diagnosis of HFpEF in a minority of patients. Incorporation of flow-corrected PAWP measures in the definition of HFpEF (PAWP_M ≥ 25 mmHg and/or PAWP_M/CO slope > 2 mmHg·L·min⁻¹) might maximise the diagnostic yield of exercise right heart catheterisation especially in those patients with peak PAWP just below 25 mmHg, without the need to resort to a simultaneous left heart catheterisation.

Provenance: Submitted article, peer reviewed.

Acknowledgements: The authors are indebted with the nurses of the catheterisation laboratory for their support in data acquisition. The authors are grateful to Laboratori Guidotti S.p.A. for providing software free of charge for echocardiographic analysis.

Support statement: This study was supported by the Italian Ministry of Health (5×1000). C. Baratto is the recipient of a research grant from the European Society of Cardiology. A. Bondue received support from the Belgian Fonds de la Recherche Scientifique (grant J.0011.19), from the Erasme Foundation (ULB) and from the Belgian Cardiac Surgery Foundation. J-L. Vachiéry is the holder of the Actelion Research Chair on Pulmonary Hypertension in his department. Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest: None declared.

References

- 1 Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. *Eur Heart J* 2011; 32: 670–679.
- 2 Caravita S, Iacovoni A, Senni M. The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room? *Eur J Heart Fail* 2021; 23: 1659–1661.
- 3 Sorimachi H, Burkhoff D, Verbrugge FH, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2021; 23: 1648–1658.
- 4 Baratto C, Caravita S, Soranna D, et al. Current limitations of invasive exercise hemodynamics for the diagnosis of heart failure with preserved ejection fraction. *Circ Heart Fail* 2021; 14: e007555.
- 5 Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail* 2010; 3: 588–595.
- 6 Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. *Circulation* 2019; 140: 353–365.
- 7 Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J* 2019; 40: 3297–3317.
- 8 Houston BA, Tedford RJ. What we talk about when we talk about the wedge pressure. *Circ Heart Fail* 2017; 10: e004450.
- 9 Baratto C, Caravita S, Soranna D, et al. Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *ESC Heart Fail* 2022; 9: 3079–3091.
- 10 Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. *Chest* 2009; 136: 37–43.
- 11 Ryan JJ, Rich JD, Thiruvoipati T, et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. *Am Heart J* 2012; 163: 589–594.
- 12 Bitar A, Selej M, Bolad I, et al. Poor agreement between pulmonary capillary wedge pressure and left ventricular end-diastolic pressure in a veteran population. *PLoS One* 2014; 9: e87304.
- 13 Oliveira RK, Ferreira EV, Ramos RP, et al. Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. *J Heart Lung Transplant* 2014; 33: 157–162.
- 14 Dickinson MG, Lam CS, Rienstra M, et al. Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. *Eur J Heart Fail* 2017; 19: 1483–1490.
- 15 Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2022; 43: 3618–3731.
- 16 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015; 16: 233–270.
- 17 Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018; 138: 861–870.
- 18 Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. *Eur Respir J* 2017; 50: 1700578.
- 19 Bastos MB, Burkhoff D, Maly J, et al. Invasive left ventricle pressure-volume analysis: overview and practical clinical implications. *Eur Heart J* 2020; 41: 1286–1297.
- 20 Reddy YNV, El-Sabbagh A, Nishimura RA. Comparing pulmonary arterial wedge pressure and left ventricular end diastolic pressure for assessment of left-sided filling pressures. *JAMA Cardiol* 2018; 3: 453–454.
- 21 Baratto C, Caravita S, Perego GB, et al. Stiff left atrial syndrome after low-dose radiotherapy for right breast cancer: the need for invasive hemodynamics at exercise. *Catheter Cardiovasc Interv* 2020; 95: 1059–1061.
- 22 Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. *Eur Respir J* 2019; 53: 1801897.

- 23 Hsu S, Fang JC, Borlaug BA. Hemodynamics for the heart failure clinician: a state-of-the-art review. *J Card Fail* 2022; 28: 133–148.
- 24 Caravita S, Baratto C. Understanding mechanisms of fontan failure: exercise hemodynamics to unmask diastolic dysfunction, Again! *Eur J Heart Fail* 2023; 25: 26–29.
- 25 Verbrugge FH, Omote K, Reddy YNV, *et al.* Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. *Eur Heart J* 2022; 43: 1941–1951.